Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Diabetes Metab Res Rev. 2021 Apr 9;37(8):e3452. doi: 10.1002/dmrr.3452

Table 2:

The proportion of patients with non-invasive prognostic tests exceeding threshold for fibrosis by patient-level summary statistic (N=6,506).

Clinical Thresholds
FIB-4 % > 1.3 (n) % > 2.67 (n)

Mean 37.3% (2,424) 5.4% (354)
Median 32.7% (2,125) 3.5% (229)
Maximum 61.9% (4,029) 20.3% (1,320)
Minimum 14.9% (970) 1.3% (87)

NFS % > −1.455 (n) % > 0.676 (n)

Mean 48.5% (3,157) 8.0% (519)
Median 48.4% (3,149) 7.9% (516)
Maximum 68.8% (4,475) 23.2% (1,510)
Minimum 27.3% (1,774) 2.9% (190)

FIB-4 OR NFS % > 1.3 OR −1.455 (n) % > 2.67 OR 0.676 (n)

Mean 56.9% (3,703) 11.2% (731)
Median 55.3% (3,598) 9.8% (638)
Maximum 76.0% (4,947) 30.6% (1,990)
Minimum 31.5% (2,052) 3.7% (240)

FIB-4 AND NFS % > 1.3 AND −1.455 (n) % > 2.67 AND 0.676 (n)

Mean 28.9% (1,878) 2.2% (142)
Median 25.8% (1,676) 1.6% (107)
Maximum 54.7% (3,557) 12.9% (840)
Minimum 10.6% (692) 0.6% (37)